Jason Lettiere is VP, Business Development at Neurvati Neurosciences and GRIN Therapeutics. He has more than 15 years of experience executing on a range of strategic initiatives including business development and licensing, financial matters, portfolio management and commercial planning at both public and private high-growth biotechnology companies. Prior to joining Neurvati, Jason was Vice President of Business Development at Terns Pharmaceuticals, Inc., where he was responsible for developing a comprehensive business development strategy from initial outreach and evaluation through signing. Prior to Terns, Jason spent nearly four years supporting business and corporate development at Neurogene Inc. and he was also formerly a member of the healthcare investment banking team at Bank of America. Earlier in his career, he held roles of increasing responsibility across commercial, strategy and business development at Intercept Pharmaceuticals. Jason received his BS in Economics and Finance from Bentley University.